Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DBV TECHNOLOGIES SA. We currently have 2 research reports from 1 professional analysts.
|05Apr17 06:31||GNW||DBV Technologies to Attend the 10th Kempen Life Sciences Conference|
|30Mar17 21:30||GNW||DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination|
|22Mar17 21:30||GNW||DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F|
|15Mar17 06:30||GNW||DBV Technologies Reports Full Year 2016 Financial Results|
|10Mar17 06:30||GNW||DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children|
|05Mar17 20:45||GNW||DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children|
|01Mar17 06:30||GNW||DBV Technologies to Attend Upcoming Investor Conferences|
Frequency of research reports
Research reports on
DBV TECHNOLOGIES SA
DBV TECHNOLOGIES SA
Enlarged Phase III PEPITES study starts
09 Dec 15
DBV has now started the Phase III Viaskin Peanut trial (PEPITES), which has been enlarged to meet patient and investigator demand, a positive sign for future potential uptake. The Phase II Viaskin Milk trial (SMILEE) has also started as a potential treatment for EoE, a food-allergy related disease. The EoE trial broadens DBV’s focus beyond traditional food allergy, which includes peanut, cow’s milk and hen’s egg allergy.
Further VIPES responder analyses at EAACI
11 Jun 15
Additional data from DBV’s Phase IIb VIPES trial have been presented at EAACI. A further post hoc analysis applying more rigorous efficacy criteria reinforces the strength of the existing data, in our view. DBV also hosted a well-attended physician symposium, highlighting interest in DBV’s Viaskin products and helping to raise broader awareness, both key for a successful launch. Our valuation is largely unchanged at €1,201m.
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
N+1 Singer - Morning Song 24-04-2017
24 Apr 17
First Derivatives (FDP LN) FY slightly ahead as strong trading momentum continues | Goals Soccer Centres (GOAL LN) A potentially exciting corporate development | mporium Group (MPM LN) 2016 results: course set for exciting 2017 | Vectura Group (VEC LN) VR315 risk outweighs longer-term potential
Positive top-line results in first iclaprim phase III clinical trial (REVIVE-1)
18 Apr 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, announced positive results this morning in the first of its two iclaprim phase III clinical trials, REVIVE-1, comparing iclaprim to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Iclaprim, a next-generation antibiotic targeting an underutilised mechanism of action which causes rapid killing of bacteria, is being developed for the treatment of serious and life threatening bacterial infections. On the key primary endpoint in the study, early clinical response at 48-72 hours after drug treatment began, 80.9% of patients on iclaprim achieved a positive response compared to 81.0% of patients on vancomycin, well within the 10% non-inferiority margin required by the FDA. Iclaprim was also shown to be safe and well-tolerated compared to vancomycin. With these positive results from REVIVE-1 we have increased the probability of success for the iclaprim development program from 65% to 75% raising our risk-adjusted NPV for Motif Bio to almost £240m or 122p per share (previously £210m and 107p per share).
N+1 Singer - Sinclair Pharma - EBITDA upgrade for 2017, but lower TP due to warranty claim and costs
19 Apr 17
We have updated product-level forecasts and included the £10m SVB debt facility and £5m warranty claim settlement with Alliance Pharma in our forecasts. The 6.3% upgrade to our FY2017 sales estimate (from £46.0m to £48.9m) brings expected EBITDA profitability forward by one year (to FY2017 from FY2018). We remain positive on the ongoing rollout of Silhouette Instalift® in particular and retain our Buy recommendation. However, higher expected sales & marketing costs and the warranty claim weigh on our valuation: we downgrade our target price from 42p to 37p.
24 Apr 17
Lok’nStore* (LOK): Growth supported by a strong balance sheet (CORP) | Mortice* (MORT): UK acquisition (CORP) | Avacta* (AVCT): Another milestone – 1st non-therapeutics licence (CORP) | Petra Diamonds (PDF): Trading update and Q3 results (BUY) | Nasstar* (NASA): Growth and margin focus (CORP)